Clinical trials

There is a worldwide research effort underway to develop new and effective treatments for MND. The only drug licenced in the UK is riluzole, which slows down the progression of MND. A great deal has already been learnt about how clinical trials should and should not be carried out, paving the way to future trials.

It is important to remember that clinical trials are not treatments but scientific experiments. Due to the design of clinical trials, participants may not receive the new drug under investigation and may experience some side effects.

How do clinical trials proceed?

Traditionally, clinical trials are divided into four phases as described below. However, with increasingly complex trial designs the distinction between Phase II and Phase III trials often becomes blurred.

What makes a good clinical trial?

Anybody could claim to have tested a treatment in a clinical trial but how would you know if their results were reliable? What makes for a really rigorous test of a potential new treatment?

A placebo controlled, double-blind, randomised clinical trial on a large number of participants, which is published in a reputable journal, is deemed a good clinical trial. Genuine and trustworthy trials will never expect participants to make any payment.

If you are told that a treatment has been tested in clinical trials, ask for more details and find out if the trial design included:

If you have any questions about MND clinical trials and treatments you can contact our Research Development team.

For further information and support contact our MND Connect helpline

mndconnect 0808 802 6262